Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 16/20 | 0.43 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4530292 | 0.95 | HSD11B1 (0.50) | HSD11B1HSD11B2NR1I2 | |
| SCHEMBL4535030 | 0.86 | HSD11B1 (0.53) | HSD11B1HSD11B2NR1I2CYP2C19 | |
| SCHEMBL5637935 | 0.81 | HSD11B1 (0.55) | HSD11B1HSD11B2NR1I2 | |
| SCHEMBL4528572 | 0.81 | HSD11B1 (0.63) | HSD11B1HSD11B2MAPK14NR1I2CYP2C19 | |
| SCHEMBL826913 | 0.78 | HSD11B1 (0.69) | HSD11B1HSD11B2NR1I2CYP2C19CYP3A4 | |
| SCHEMBL826912 | 0.78 | HSD11B1 (0.69) | HSD11B1HSD11B2NR1I2CYP2C19CYP3A4 | |
| SCHEMBL4360892 | 0.76 | HSD11B1 (0.60) | HSD11B1HSD11B2NR1I2CYP2C19 | |
| SCHEMBL16868571 | 0.72 | HSD11B1 (0.83) | HSD11B1HSD11B2NR1I2CYP2C19CYP3A4 | |
| SCHEMBL12020391 | 0.72 | HSD11B1 (0.47) | HSD11B1HSD11B2MAPK14NR1I2 | |
| SCHEMBL1108885 | 0.69 | HSD11B1 (0.48) | HSD11B1HSD11B2NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1532122-B1 | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK SHARP & DOHME (US) | 2011-12-14 | — | — | EP | disclosed |
| EP-1532122-B1 | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK SHARP & DOHME (US) | 2011-12-14 | — | — | EP | disclosed |
| US-7179802-B2 | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179802-B2 | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179802-B2 | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-6730690-B2 | DELAYING THE ONSET OR REDUCING THE RISK OF DEVELOPING ATHEROSCLEROSIS IN A HUMAN PATIENT COMPRISING ADMINISTERING TO SAID PATIENT AN EFFECTIVE AMOUNT OF A COMPOUND OF INVENTION AND AN HMG-COA REDUCTASE INHIBITOR | MERCK & CO., INC. | 2004-05-04 | — | — | US | disclosed |